Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!

Wedbush Recommends Buying Cidara Shares After Rezafungin Deal

Courtesy of Benzinga

Wedbush Recommends Buying Cidara Shares After Rezafungin Deal

Cidara Therapeutics Inc (NASDAQ: CDTX) announced a development and commercialization deal Tuesday for its lead antifungal investigational drug, rezafungin.

The Analyst

Wedbush analyst Robert Driscoll upgraded Cidara from Neutral to Outperform and upped the price target from $2 to $4.

The Thesis

Cidara’s partnership with Mundipharma is a significant positive, given the $30-million upfront payment, $9-million equity investment and near-term payments of $42 million, Driscoll said in a Tuesday upgrade note. (See his track record here.) 

In return, Mundipharma receives global commercial rights to rezafungin excluding the U.S. and Japan, the analyst said. 

Wedbush sees the total deal value to be in excess of $534 million.

The equity investment will be enacted by way of a private placement of 4.78 million new shares issued at $1.884 each, a 20% premium to the 10-day volume weighted average price, he said. 

“Additionally, we see substantial synergies between both companies given Mundipharma already has a significant global commercial reach with annual sales over €2B in a variety of therapeutic areas including diabetes, respiratory, oncology, pain and biosimilars,” Driscoll said. 

The firm recommends buying Cidara shares given the removal of the financing overhang as well as an improving reimbursement environment for antibacterials and antifungals.

Specifically, Wedbush encourages long-term investors to buy into the shares ahead of the mid-2020 Phase 3 ReSTORE data readout.

The Price Action

Following the roughly 40% rally on Tuesday, Cidara shares were giving back some of the gains, trading down 11.91% at $2.07 at the time of publication Wednesday. 

Related Links:

The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq’s Good Books

Cidara Rallies On Development Deal For Lead Antifungal Medication

Latest Ratings for CDTX

Date Firm Action From To
Sep 2019 Upgrades Neutral Outperform
Jun 2019 Initiates Coverage On Outperform
May 2019 Downgrades Outperform Neutral

View More Analyst Ratings for CDTX


View the Latest Analyst Ratings

Posted-In: Robert Driscoll WedbushAnalyst Color Biotech Upgrades Price Target Analyst Ratings General


Do you know someone who would benefit from this information? We can send your friend a strictly confidential, one-time email telling them about this information. Your privacy and your friend's privacy is your business... no spam! Click here and tell a friend!





You must be logged in to make a comment.
You can sign up for a membership or get a FREE Daily News membership or log in

Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!